Question: In your normal clinical practice which tests would you do at this stage?
Answer: Most would recommend a stress echocardiogram, nuclear perfusion scan, or an magnetic resonance imaging (MRI) perfusion scan.
Exercise ECG is not usually any longer recommended particularly as this is a female patient in whom the exercise ECG is considered by many to be unreliable. Invasive or non-invasive definition of the anatomy is probably unnecessary before further treatment in view of the mild symptomatic status of the patient. We performed an MRI perfusion scan (Figure 1 ) which demonstrated inferior reversible perfusion defect.
Treatment for the patient was considered: importance of lifestyle advice; in particular stopping smoking as well as taking more regular exercise was considered essential. Aspirin 75-100 mg daily was also recommended. Atorvastatin 10 mg was also recommended in spite of the fact that the LDL was well controlled and HDL was also appropriate. Angiotensin converting enzyme (ACE) inhibitor in the form of perindopril was not considered for this patient although some may have started Perindopril 8 mg for prognosis. Bisoprolol 5 mg was started for the management of angina. There was no indication for the use of ivabradine, calcium antagonist, or nicorandil at this stage; nor was there a need, as the patient was only mildly symptomatic, to consider coronary angiography and referral for coronary angioplasty.
The patient's main concern was not her angina but the effect the angina would have on her prognosis particularly as she had teenage children to bring up. It was generally considered that cardiovascular risk of death was around about 1% per annum which would not be modified by any interventional procedure. She was reassured with this information.
Six months later the patient was seen; she had made no changes to her lifestyle and in particular continued to smoke. Her chest pain remained mild (CCS Class I). Her heart rate 72 b.p.m. and blood pressure 130/80 mmHg with a LDL of 70 mg/dL.
She was again advised about the importance of stopping smoking and sent for counselling as well as prescribed a course of rehabilitation with no changes in her pharmacological treatment recommended.
A further 6 months later the patient's condition deteriorated modestly to CCS Class II, but this did not interfere with her everyday life. She had stopped smoking, was taking more exercise following the rehabilitation clinic. Her heart rate was 70 b.p.m., blood pressure 110/70 mmHg, LDL 70 mg/dL.
A decision was made to perform a coronary angiogram which showed (Figure 2 ) a flow limiting lesion in a dominant right coronary artery (functional flow reserve (FFR) 0.74), and an unobstructed left coronary system.
The question of whether to proceed to coronary angioplasty of this lesion was discussed. Overall the consensus was to continue to manage her medically and ivabradine 5 mg b.i.d. was added to her treatment. Ivabradine was selected because the heart rate of 70 b.p.m., blood pressure of 110/70 mmHg suggests that this a more appropriate treatment than increasing the dose of betablocker and risking further lowering of blood pressure or introducing a calcium antagonist and further lowering blood pressure.
Three months later the patient remained well with mild angina (CCS Class I), heart rate 64 b.p.m. and blood pressure 110/70 mmHg.
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